- Last session on Wall Street this week starts with moderate declines
- Financial sector earnings season for Q4 2021
- US sales data disappoints!
- Senate blocks vaccine obligation for large private companies
The last trading session on Wall Street this week brings moderate declines, caused by the retreat of shares of financial companies after the start of the season of publication of results for the fourth quarter of 2021. Investors also learned retail sales data, which slightly disappointed the market and showed that Americans are slowing the pace of shopping.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appThe US30 index is down around 0.6% at the start of today's trading and is testing the support set by the confluence of the 38.2% Fibo retracement and the EMA 50 (blue line). If the supply side manages to continue declines, the next potential level for a rebound is the area of 50% retracement and EMA 100 (purple line). Local resistance remains near 36,100 points. Source: xStation 5
News:
Today begins the period of publishing financial results by major banks and other financial institutions. JP Morgan (JPM.US) Citigroup (C.US), Wells Fargo (WFC.US) and BlackRock (BLK.US) released their results before the start of trading in the US today. The banks delivered better revenue results than analysts had expected, but EPS ratios for individual institutions were rather mixed. Before the US market opened, JPM.US shares lost nearly 4.5%, WFC.US gained 1%, C.US dived 4% and BLK.US lost 2.3%. As a reminder:
JP Morgan (JPM.US)
Revenue - $30.35 billion (expected - $29.9 billion)
Net profit - $10.14 billion (previously - $12.14 billion)
EPS - $3.33 (expected - $3.79)
Wells Fargo (WFC.US)
Revenue - $20.86 billion (expected $18.85 billion)
EPS - $1.38 (expected - $1.02)
Citigroup (C.US)
Revenue - $17.02 billion (expected - $16.80 billion)
EPS - $1.99 (expected - $1.62)
BlackRock (BLK.US)
Revenue - $5.11 billion (expected - $5.16 billion)
EPS - $10.42 (expected - $10.15)
Assets under management -$10.1 trillion (expected - $9.85 trillion)
JP Morgan (JPM.US) shares opened today with a huge gap down and are losing the most since 2020, diving more than 6%. Currently, the company's shares are testing the support set by the EMA 200 (gold line). Source: xStation 5
Retail sales data from the US showed a strong decline on the month. Retail sales fell by 1.9% in December, against expectations of a 0.1% monthly decline. This is the first decline since August and the largest since March. Core sales also disappointed and showed a 2.3% month-on-month decline (a 0.2% increase was expected).
Medical companies are diving today after the Supreme Court blocked President Biden's adminitration of a vaccine or testing mandate for large corporations. Novavax (NVAX.US) shares are losing nearly 15% before the session opens on Wall Street. Moderna (MRNA.US) is down 5% and Pfizer (PFE.US) is losing 2%.
President Biden nominated Ms. Sarah Bloom Raskin as the Federal Reserve's next vice chair for supervision.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
